NEWS
ANFIDA
Check category

Policy innovation breaks the bottleneck, proactively strikes out to find a new life-the joint dynamic cartilage regeneration project ushered in new opportunities for development

  • Categories:Industry News
  • Author:
  • Origin:
  • Time of issue:2020-04-08 11:12
  • Views:

(Summary description)April 21, Tianjin Northnet News: After more than half a year of demonstration in the Tianjin Pilot Free Trade Zone, the "Report on the Pilot Test of Cell Therapy in the Tianjin Pilot Free Trade Zone" was drafted and then submitted to the Ministry of Commerce of the People’s Republic of China, and the Municipal Health The health, drug supervision, and technology departments jointly organize industry regulatory organizations to promote the admission of low- and medium-risk cell therapy products with medical technology and carry out clinical applications. Patients with related diseases can directly enjoy cell diagnosis and treatment in the Tianjin Pilot Free Trade Zone and the Joint Innovation Zone. Scientific research institutions and cell technology-related companies can also let go of research and realize clinical translational applications more quickly. Joint Power Biotechnology Co., Ltd., a subsidiary of Tianjin Anda Group, firmly seized the opportunity to focus on the world's leading technology in the regeneration and repair of autologous cartilage cells. The District Bureau of Science and Industry established contacts, introduced the company's development history, provided detailed technical materials for the project, and invited them to the company for inspection and guidance.

Policy innovation breaks the bottleneck, proactively strikes out to find a new life-the joint dynamic cartilage regeneration project ushered in new opportunities for development

(Summary description)April 21, Tianjin Northnet News: After more than half a year of demonstration in the Tianjin Pilot Free Trade Zone, the "Report on the Pilot Test of Cell Therapy in the Tianjin Pilot Free Trade Zone" was drafted and then submitted to the Ministry of Commerce of the People’s Republic of China, and the Municipal Health The health, drug supervision, and technology departments jointly organize industry regulatory organizations to promote the admission of low- and medium-risk cell therapy products with medical technology and carry out clinical applications. Patients with related diseases can directly enjoy cell diagnosis and treatment in the Tianjin Pilot Free Trade Zone and the Joint Innovation Zone. Scientific research institutions and cell technology-related companies can also let go of research and realize clinical translational applications more quickly.

Joint Power Biotechnology Co., Ltd., a subsidiary of Tianjin Anda Group, firmly seized the opportunity to focus on the world's leading technology in the regeneration and repair of autologous cartilage cells. The District Bureau of Science and Industry established contacts, introduced the company's development history, provided detailed technical materials for the project, and invited them to the company for inspection and guidance.

  • Categories:Industry News
  • Author:
  • Origin:
  • Time of issue:2020-04-08 11:12
  • Views:
Information
April 21, Tianjin Northnet News: After more than half a year of demonstration in the Tianjin Pilot Free Trade Zone, the "Report on the Pilot Test of Cell Therapy in the Tianjin Pilot Free Trade Zone" was drafted and then submitted to the Ministry of Commerce of the People’s Republic of China, and the Municipal Health The health, drug supervision, and technology departments jointly organize industry regulatory organizations to promote the admission of low- and medium-risk cell therapy products with medical technology and carry out clinical applications. Patients with related diseases can directly enjoy cell diagnosis and treatment in the Tianjin Pilot Free Trade Zone and the Joint Innovation Zone. Scientific research institutions and cell technology-related companies can also let go of research and realize clinical translational applications more quickly.
 
Joint Power Biotechnology Co., Ltd., a subsidiary of Tianjin Anda Group, firmly seized the opportunity to focus on the world's leading technology in the regeneration and repair of autologous cartilage cells. The District Bureau of Science and Industry established contacts, introduced the company's development history, provided detailed technical materials for the project, and invited them to the company for inspection and guidance.

  On May 12th, Chen Mingye, director of the Policy Research Office of the Binhai New Area Innovation and Development Bureau, led Wang Jing, the senior director of biotechnology projects, to Joint Power Biotechnology Co., Ltd. and discussed the cartilage regeneration project with Yuan Jizu, General Manager of Anda Group, and Chen Ming, General Manager of Joint Power Through discussions and discussions, a preliminary consensus was reached on efforts to include the cartilage regeneration project in the pilot promotion plan of cell therapy in the free trade zone, and the opinions on arranging for district leaders to be invited to visit were put forward.

 
Led by the Innovation Bureau, it will conduct a comprehensive evaluation of the project in conjunction with the Health and Health Commission, the Food and Drug Administration, and related hospitals, and integrate application scenarios as soon as possible to break through the bottleneck of corporate development with policy innovation.

On June 10th, full-time deputy director of the China (Tianjin) Pilot Free Trade Zone Management Committee, deputy head of Tianjin Binhai New Area People’s Government and director of Binhai New Area Innovation and Development Bureau Yin Xiaofeng, led by Deputy Director of Innovation and Development Bureau Zhou Minhua, free trade zone airport area He Jiang, director of the work bureau, and staff from related departments came to Joint Power. They first visited the purification workshop and learned about the production process, and then had a long discussion in the conference room. Group General Manager Yuan Jizu first expressed welcome and thanks to Director Yin Xiaofeng and his delegation on behalf of Chairman Cui Hongjin, and introduced the overall situation of the group. Chen Ming, general manager of Joint Power, elaborated on the company's development history, technological leadership, safety and effectiveness, possible economic and social benefits, difficulties encountered before, and urgent problems to be solved, and answered everyone one by one. Question. Deputy District Chief Yin Xiaofeng fully recognized the cartilage regeneration technology. After analyzing the difficulties encountered by the company, he put forward specific solutions. He said: The joint dynamics technology is a good technology that benefits the people and can effectively solve the common people. The pain caused by osteoarthritis, but due to the lack of policy guidance, it has not been fully promoted. This time, it is necessary to break through the bottleneck through policy innovation, system innovation, and pioneering trials. The core problem of cell therapy is application, and only find applications Only when clinical experts approve and apply the scenarios can the real value be realized. In the next step, we must work hard to find clinical application scenarios for enterprises, and organize and coordinate relevant departments to do a good job of docking services. According to the suggestion put forward by the Deputy District Mayor Yin Xiaofeng, Joint Power Company cooperated with relevant departments to make a detailed plan to carry out docking work with three clinical hospitals in the free trade zone, and strive to realize clinical application as soon as possible. Wang Junpeng, assistant to the chairman of the group, also attended the meeting.

On June 11, the Binhai New Area Innovation Development Bureau, Joint Power Company, and Tianjin Medical University General Hospital jointly held a symposium to discuss the clinical application of cartilage regeneration technology. Chen Mingye, Director of the Policy Research Office of the Innovation Bureau, Wang Jing, Senior Director, and Deputy General Hospital Li Hui, Dean and Director of Orthopedics Center, Zhang Yuan, Director of Trauma Surgery of Orthopedics Center, Zhang Huafeng, Deputy Director of Joint Surgery, Li Zhijun, attending physician of Joint Surgery and postdoctoral fellow of Stanford University, and Chen Ming, General Manager of Joint Power Company attended the event. The meeting was presided over by Chen Mingye, Director of the Office of Innovation Bureau. He first introduced the theme of the meeting and the overall plan of the Binhai New Area Innovation Bureau for the clinical access policy of cell therapy. He gave high praise to Joint Power Company’s cartilage cell regeneration technology, and he planned to serve as the first Three pilot projects in the free trade zone will be clinically promoted.
General Manager Chen Ming introduced the development process and advantages of CaRes technology in detail, and shared the clinical cases done over the years with clinical experts present. During the period, Vice President Li Hui and his orthopedic team members listened carefully and communicated in depth, and everyone agreed. It is believed that CaRes is a safe and effective clinical technology for the treatment of cartilage injury, which is worthy of clinical promotion, and it is proposed that the technology has been available for more than ten years. Starting with cell viability and improving surgical methods, the original open surgery is upgraded to minimally invasive surgery, which greatly reduces the trauma of patients and improves the efficiency of surgery. This technology has become the only standardized clinical practice in China that patients are willing to accept and are clinically convenient. technology.
Director Chen Mingye pointed out in the final summary that this meeting truly embodies the positioning of the Free Trade Zone Innovation Bureau for the clinical access policy of cell therapy technology. We will continue to follow up on this project, provide all guarantees, and escort Joint Power Company's cartilage regeneration technology to achieve full clinical access as soon as possible, to achieve economic benefits for enterprises, achieve social benefits for clinics, and contribute to the relief of illnesses for the people.
Previous: None
Next: None
Previous: None
Next: None

FEEDBACK

WRITE A MESSAGE TO US

Username used for comment:
Feedback
Description:

Releate News

Previous page
1

Contact Us

We have always regarded customer satisfaction as our goal and have been highly praised by customers at home and abroad.

Hotlink:Anda Group     Copyright © 2021 ANFIDA. All rights reserved.       津ICP备09042556号        津公网安备12011002024060号       Powered by www.300.cn

ANFIDA